Fortrea Holdings Inc. reported third-quarter revenues of $691.5 million and adjusted diluted earnings per share of $0.28 for the period ended September 30, 2026. The company raised its full-year revenue guidance midpoint to $2,677.5 million and adjusted EBITDA midpoint to $214 million, while narrowing the ranges for both metrics. GAAP net income was $0.6 million, or $0.01 per diluted share, compared to a loss in the prior year period. The firm also reported free cash flow of $52.5 million and adjusted backlog of $7.3 billion as of quarter-end. Fortrea is a leading global contract research organization providing clinical development solutions to the life sciences industry.
